Document is current
Any future updates will be listed below
-
Authors
Kovatcheva, Marta https://orcid.org/0000-0002-2536-1043
Melendez, Elena https://orcid.org/0000-0002-5584-1179
Chondronasiou, Dafni
Pietrocola, Federico
Bernad, Raquel https://orcid.org/0000-0002-9003-1323
Caballe, Adrià https://orcid.org/0000-0002-2388-4713
Junza, Alexandra
Capellades, Jordi
Holguín-Horcajo, Adrián https://orcid.org/0000-0002-5447-6181
Prats, Neus
Durand, Sylvere
Rovira, Meritxell https://orcid.org/0000-0002-0538-4846
Yanes, Oscar https://orcid.org/0000-0003-3695-7157
Stephan-Otto Attolini, Camille https://orcid.org/0000-0001-8045-320X
Kroemer, Guido https://orcid.org/0000-0002-9334-4405
Serrano, Manuel https://orcid.org/0000-0001-7177-9312
- License Information
-
More Information
Article History
Received: 11 October 2022
Accepted: 27 September 2023
First Online: 16 November 2023
Competing interests
: G.K. holds research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Tollys and Vascage. G.K. is on the Board of Directors of the Bristol Myers Squibb Foundation France. G.K. is a scientific cofounder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. G.K. is on the scientific advisory boards of Hevolution, Institut Servier and Longevity Vision Funds. G.K. is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. G.K.’s wife, L. Zitvogel, has held research contracts with Glaxo Smyth Kline, Incyte, Lytix, Kaleido, Innovate Pharma, Daiichi Sankyo, Pilege, Merus, Transgene, 9 m, Tusk and Roche, was on the on the Board of Directors of Transgene, is a cofounder of everImmune, and holds patents covering the treatment of cancer and the therapeutic manipulation of the microbiota. G.K.’s brother, R. Kroemer, was an employee of Sanofi and now consults for Boehringer-Ingelheim. M.K. has ongoing or completed research contracts with Galapagos, Rejuveron Senescence Therapeutics and Mesoestetic. D.C. is an employee of Fenix Group International. M.S. is shareholder of Senolytic Therapeutics, Life Biosciences, Rejuveron Senescence Therapeutics, and Altos Labs. M.S. was consultant until the end of 2022 of Rejuveron Senescence Therapeutics and Altos Labs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The other authors declare no competing interests.
